** Shares of drug developer Fractyl Health GUTS.O rise 1.4% to $1.49 premarket
** Co says obesity gene therapy RJVA-002 showed ~30% weight loss in mice, in a preclinical trial
** The therapy is designed to trigger the production of appetite-suppressing hormones, GLP-1 and GIP
** Treatment with RJVA-002 resulted in a dose-dependent reduction in body weight - Fracty
** Up to last close, stock down ~28% YTD
(Reporting by Sahil Pandey in Bengaluru)
((Sahil.Pandey@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.